Ligelizumab

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Ligelizumab
Monoclonal antibody
Type Whole antibody
Source Humanized (from mouse)
Target IGHE
Clinical data
Synonyms QGE031
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
Chemical and physical data
Formula C6534H10000N1716O2038S44
Molar mass 146.6 kDa

Ligelizumab (QGE031) (INN) is a humanized monoclonal antibody designed for the treatment of severe asthma and chronic spontaneous urticaria.[1] It binds to IGHE an acts as an immunomodulator.[2]

This drug was developed by Novartis Pharma AG.

Adverse drug effects[edit]

References[edit]